Loading next page...
/lp/springer_journal/elevated-expression-of-the-ezh2-gene-in-calr-mutated-patients-with-3WFbqHBmia
- Publisher
- Springer Journals
- Copyright
- Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
- Subject
- Medicine & Public Health; Hematology; Oncology
- ISSN
- 0939-5555
- eISSN
- 1432-0584
- DOI
- 10.1007/s00277-018-3287-8
- pmid
- 29560522
- Publisher site
- See Article on Publisher Site
Abstract
Primary myelofibrosis (PMF) is one of the BCR/ABL-negative myeloproliferative neoplasms (MPNs), characterized by the diffuse fibrous hyperproliferation, bone marrow osteosclerosis, extramedullary hematopoiesis, and marked splenomegaly. The patients with PMF have an insidious onset, a long duration of clinical course, and the deteriorated quality of life. It has been reported that the CALR gene 9 exon mutations were detected in 25–30% PMF patients, particularly as high as 80% in the JAK2/MPL-negative ones. As the second most common mutation in BCR/ABL-negative MPNs, CALR mutation has been included in the latest World Health Organization (WHO) classification criteria as one of the main diagnostic criteria for both essential thrombocythemia (ET) and PMF. Moreover, the CALR mutations indicated a favorable prognosis, which the mechanism is still under investigation. It was demonstrated that a characterized high expression of EZH2 and SUZ12 in CALR-mutated patients. Taking EZH2 as the research entry point, we initially discussed the mechanism that the CALR-positive patients with PMF exhibited a better prognosis in the current study.
Journal
Annals of Hematology – Springer Journals
Published: Mar 20, 2018
Recommended Articles
Loading...
References
-
Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and managementTefferi, A
-
Update from the latest WHO classification of MPNs: a user's manualPassamonti, F; Maffioli, M
-
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changesVardiman, JW; Thiele, J; Arber, DA; Brunning, RD; Borowitz, MJ; Porwit, A; Harris, NL; Beau, MM; Hellstrom-Lindberg, E; Tefferi, A; Bloomfield, CD
-
The dynamic international prognostic scoring system for myelofibrosis predicts outcomes after hematopoietic cell transplantationScott, BL; Gooley, TA; Sorror, ML; Rezvani, AR; Linenberger, ML; Grim, J; Sandmaier, BM; Myerson, D; Chauncey, TR; Storb, R; Buxhofer-Ausch, V; Radich, JP; Appelbaum, FR; Deeg, HJ
-
Allogeneic transplantation for patients with advanced myelofibrosis: splenomegaly and high serum LDH are adverse risk factors for successful engraftmentGergis, U; Kuriakose, E; Shore, T; Mayer, S; Mark, T; Pearse, R; Schuster, M; Feldman, E; Roboz, G; Ritchie, E; Scandura, J; Wang, H; Zhou, XK; Silver, RT; Besien, K
-
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosisVerstovsek, S; Mesa, RA; Gotlib, J; Levy, RS; Gupta, V; DiPersio, JF; Catalano, JV; Deininger, M; Miller, C; Silver, RT; Talpaz, M; Winton, EF; Harvey, JJ; Arcasoy, MO; Hexner, E; Lyons, RM; Paquette, R; Raza, A; Vaddi, K; Erickson-Viitanen, S; Koumenis, IL; Sun, W; Sandor, V; Kantarjian, HM
-
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patientsPolverelli, N; Breccia, M; Benevolo, G; Martino, B; Tieghi, A; Latagliata, R; Sabattini, E; Riminucci, M; Godio, L; Catani, L; Nicolosi, M; Perricone, M; Sollazzo, D; Colafigli, G; Campana, A; Merli, F; Vitolo, U; Alimena, G; Martinelli, G; Lewis, RE; Vianelli, N; Cavo, M; Palandri, F
-
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosisHarrison, C; Kiladjian, JJ; Al-Ali, HK; Gisslinger, H; Waltzman, R; Stalbovskaya, V; McQuitty, M; Hunter, DS; Levy, R; Knoops, L; Cervantes, F; Vannucchi, AM; Barbui, T; Barosi, G
-
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasmsPieri, L; Paoli, C; Arena, U; Marra, F; Mori, F; Zucchini, M; Colagrande, S; Castellani, A; Masciulli, A; Rosti, V; Stefano, V; Betti, S; Finazzi, G; Ferrari, ML; Rumi, E; Ruggeri, M; Nichele, I; Guglielmelli, P; Fjerza, R; Mannarelli, C; Fanelli, T; Merli, L; Corbizi, FG; Massa, M; Cimino, G; Rambaldi, A; Barosi, G; Cazzola, M; Barbui, T; Vannucchi, AM
-
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective studyCampbell, PJ; Scott, LM; Buck, G; Wheatley, K; East, CL; Marsden, JT; Duffy, A; Boyd, EM; Bench, AJ; Scott, MA; Vassiliou, GS; Milligan, DW; Smith, SR; Erber, WN; Bareford, D; Wilkins, BS; Reilly, JT; Harrison, CN; Green, AR
-
SomaticCALRMutations in Myeloproliferative Neoplasms with NonmutatedJAK2Nangalia, J; Massie, CE; Baxter, EJ; Nice, FL; Gundem, G; Wedge, DC; Avezov, E; Li, J; Kollmann, K; Kent, DG; Aziz, A; Godfrey, AL; Hinton, J; Martincorena, I; Loo, P; Jones, AV; Guglielmelli, P; Tarpey, P; Harding, HP; Fitzpatrick, JD; Goudie, CT; Ortmann, CA; Loughran, SJ; Raine, K; Jones, DR; Butler, AP; Teague, JW; O'Meara, S; McLaren, S; Bianchi, M; Silber, Y; Dimitropoulou, D; Bloxham, D; Mudie, L; Maddison, M; Robinson, B; Keohane, C; Maclean, C; Hill, K; Orchard, K; Tauro, S; Du, MQ; Greaves, M; Bowen, D; Huntly, BJ; Harrison, CN; Cross, NC; Ron, D; Vannucchi, AM; Papaemmanuil, E; Campbell, PJ; Green, AR
-
Somatic mutations of calreticulin in myeloproliferative neoplasmsKlampfl, T; Gisslinger, H; Harutyunyan, AS; Nivarthi, H; Rumi, E; Milosevic, JD; Them, NC; Berg, T; Gisslinger, B; Pietra, D; Chen, D; Vladimer, GI; Bagienski, K; Milanesi, C; Casetti, IC; Sant'Antonio, E; Ferretti, V; Elena, C; Schischlik, F; Cleary, C; Six, M; Schalling, M; Schonegger, A; Bock, C; Malcovati, L; Pascutto, C; Superti-Furga, G; Cazzola, M; Kralovics, R
-
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosisRumi, E; Pietra, D; Pascutto, C; Guglielmelli, P; Martinez-Trillos, A; Casetti, I; Colomer, D; Pieri, L; Pratcorona, M; Rotunno, G; Sant'Antonio, E; Bellini, M; Cavalloni, C; Mannarelli, C; Milanesi, C; Boveri, E; Ferretti, V; Astori, C; Rosti, V; Cervantes, F; Barosi, G; Vannucchi, AM; Cazzola, M
-
Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosisBarbui, T; Thiele, J; Vannucchi, AM; Tefferi, A
-
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisonsTefferi, A; Lasho, TL; Finke, CM; Knudson, RA; Ketterling, R; Hanson, CH; Maffioli, M; Caramazza, D; Passamonti, F; Pardanani, A
-
Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impactTefferi, A; Lasho, TL; Finke, C; Belachew, AA; Wassie, EA; Ketterling, RP; Hanson, CA; Pardanani, A
-
Improved survival of calreticulin-mutated patients compared with Janus kinase 2 in primary myelofibrosis: a meta-analysisKourie, HR; Ameye, L; Paesmans, M; Bron, D
-
The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapiesLuo, B; Lee, AS
-
Calreticulin signaling in health and diseaseWang, WA; Groenendyk, J; Michalak, M
-
The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasmsWu, Z; Zhang, X; Xu, X; Chen, Y; Hu, T; Kang, Z; Li, S; Wang, H; Liu, W; Ma, X; Guan, M
-
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic valueVannucchi, AM; Rotunno, G; Bartalucci, N; Raugei, G; Carrai, V; Balliu, M; Mannarelli, C; Pacilli, A; Calabresi, L; Fjerza, R; Pieri, L; Bosi, A; Manfredini, R; Guglielmelli, P
-
Calreticulin mutations in myeloproliferative neoplasmsLavi, N
-
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutationsAndrikovics, H; Krahling, T; Balassa, K; Halm, G; Bors, A; Koszarska, M; Batai, A; Dolgos, J; Csomor, J; Egyed, M; Sipos, A; Remenyi, P; Tordai, A; Masszi, T
-
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesisRampal, R; Al-Shahrour, F; Abdel-Wahab, O; Patel, JP; Brunel, JP; Mermel, CH; Bass, AJ; Pretz, J; Ahn, J; Hricik, T; Kilpivaara, O; Wadleigh, M; Busque, L; Gilliland, DG; Golub, TR; Ebert, BL; Levine, RL
-
The roles of EZH2 in cell lineage commitmentChou, RH; Yu, YL; Hung, MC
-
Role of the polycomb repressive complex 2 (PRC2) in transcriptional regulation and cancerLaugesen, A; Højfeldt, JW; Helin, K
-
Atg3 overexpression enhances bortezomib-induced cell death in SKM-1 cellZhuang, L; Ma, Y; Wang, Q; Zhang, J; Zhu, C; Zhang, L; Xu, X
-
Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignanciesKhan, SN; Jankowska, AM; Mahfouz, R; Dunbar, AJ; Sugimoto, Y; Hosono, N; Hu, Z; Cheriyath, V; Vatolin, S; Przychodzen, B; Reu, FJ; Saunthararajah, Y; O'Keefe, C; Sekeres, MA; List, AF; Moliterno, AR; McDevitt, MA; Maciejewski, JP; Makishima, H
-
Multifaceted role of the polycomb-group gene EZH2 in hematological malignanciesSashida, G; Iwama, A
-
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disordersErnst, T; Chase, AJ; Score, J; Hidalgo-Curtis, CE; Bryant, C; Jones, AV; Waghorn, K; Zoi, K; Ross, FM; Reiter, A; Hochhaus, A; Drexler, HG; Duncombe, A; Cervantes, F; Oscier, D; Boultwood, J; Grand, FH; Cross, NC
-
Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasmsScore, J; Hidalgo-Curtis, C; Jones, AV; Winkelmann, N; Skinner, A; Ward, D; Zoi, K; Ernst, T; Stegelmann, F; Dohner, K; Chase, A; Cross, NC
-
Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretionHan, L; Schubert, C; Kohler, J; Schemionek, M; Isfort, S; Brummendorf, TH; Koschmieder, S; Chatain, N
-
Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasmsAraki, M; Yang, Y; Masubuchi, N; Hironaka, Y; Takei, H; Morishita, S; Mizukami, Y; Kan, S; Shirane, S; Edahiro, Y; Sunami, Y; Ohsaka, A; Komatsu, N
-
Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulumMichalak, M; Groenendyk, J; Szabo, E; Gold, LI; Opas, M
-
Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanismGarbati, MR; Welgan, CA; Landefeld, SH; Newell, LF; Agarwal, A; Dunlap, JB; Chourasia, TK; Lee, H; Elferich, J; Traer, E; Rattray, R; Cascio, MJ; Press, RD; Bagby, GC; Tyner, JW; Druker, BJ; Dao, KH
-
Structural and functional relationships between the lectin and arm domains of calreticulinPocanschi, CL; Kozlov, G; Brockmeier, U; Brockmeier, A; Williams, DB; Gehring, K
-
Calreticulin gene mutations in myeloproliferative neoplasms without Janus kinase 2 mutationsSun, C; Zhang, S; Li, J
-
Calreticulin is a receptor for nuclear exportHolaska, JM; Black, BE; Love, DC; Hanover, JA; Leszyk, J; Paschal, BM
-
Uncovering the roles of miRNAs and their relationship with androgen receptor in prostate cancerChun Jiao, S; Huan, C; Chao Yang, X; Guo Mei, R
-
Celastrol induces autophagy by targeting AR/miR-101 in prostate cancer cellsGuo, J; Huang, X; Wang, H; Yang, H
-
MicroRNAs as regulators of signal transduction in urological tumorsFendler, A; Stephan, C; Yousef, GM; Jung, K
-
Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genesTakeshita, F; Patrawala, L; Osaki, M; Takahashi, RU; Yamamoto, Y; Kosaka, N; Kawamata, M; Kelnar, K; Bader, AG; Brown, D
-
Identification of novel AR-targeted microRNAs mediating androgen signalling through critical pathways to regulate cell viability in prostate cancerMo, W; Zhang, J; Li, X; Meng, D; Gao, Y; Yang, S; Wan, X; Zhou, C; Guo, F; Huang, Y; Amente, S; Avvedimento, EV; Xie, Y; Li, Y
-
Prolonged Ezh2 depletion in glioblastoma causes a robust switch in cell fate resulting in tumor progressionVries, NA; Hulsman, D; Akhtar, W; Jong, J; Miles, DC; Blom, M; Tellingen, O; Jonkers, J; Lohuizen, M
@Phil_Robichaud
@deepthiw
@JoseServera